| Code | CSB-RA023974MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to BLENREP, targeting TNFRSF17 (also known as BCMA, B-cell maturation antigen), a member of the tumor necrosis factor receptor superfamily. TNFRSF17 is predominantly expressed on mature B cells and plasma cells, where it plays a critical role in B-cell survival, differentiation, and antibody production through interactions with its ligands BAFF and APRIL. This receptor exhibits restricted expression patterns in normal tissues but demonstrates high expression on malignant plasma cells in multiple myeloma, making it an attractive therapeutic target for hematological malignancies.
BLENREP (belantamab mafodotin) is an FDA-approved antibody-drug conjugate that binds to TNFRSF17 and delivers a cytotoxic payload specifically to BCMA-expressing cells, demonstrating clinical efficacy in relapsed or refractory multiple myeloma. This biosimilar antibody serves as a valuable research tool for investigating BCMA biology, exploring plasma cell disorders, evaluating immune cell interactions, and supporting preclinical studies in oncology and immunology. It enables researchers to examine TNFRSF17-mediated signaling pathways and assess potential therapeutic strategies targeting this receptor.
There are currently no reviews for this product.